Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ritanserin improves sleep quality in narcolepsy.

G Mayer1

  • 1Hephata Klinik, Schwalmstadt-Treysa, Germany. geert.mayer@hephata.com

Pharmacopsychiatry
|August 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, blinded, prospective trial to compare the safety and efficacy of three bowel-cleansing solutions for colonoscopy (HSG-01*).

Endoscopy·2003
Same author

Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations.

Pharmacogenomics·2003
Same author

Study of a patient population investigated for excessive daytime sleepiness (EDS).

Neurophysiologie clinique = Clinical neurophysiology·2003
Same author

HLA and genetic susceptibility to sleepwalking.

Molecular psychiatry·2003
Same author

[Ultrasonic diagnosis of calciphylactic lesions].

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2003
Same author

Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses.

Neurology·2002
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same journal

A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

Pharmacopsychiatry·2026
Same journal

High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.

Pharmacopsychiatry·2026
Same journal

Great Expectations, Limited Evidence: The Emerging Role of Artificial Intelligence in Pharmacopsychiatry.

Pharmacopsychiatry·2026
Same journal

Rates of Hypoprolactinemia in Bipolar Patients Receiving Once-monthly Long-acting Injectable Aripiprazole.

Pharmacopsychiatry·2026
Same journal

Clinical and Neurobiological Findings in a Patient With Unipolar Depressive 48-hour-ultrarapid-cycling.

Pharmacopsychiatry·2026
See all related articles

Ritanserin, a 5HT2-antagonist, improved morning refreshment in narcolepsy patients but did not significantly reduce daytime sleepiness or sleep attacks. It may help improve sleep quality as an add-on treatment.

Area of Science:

  • Neurology
  • Sleep Medicine
  • Pharmacology

Background:

  • Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness and disrupted sleep.
  • Ritanserin, a selective serotonin 5HT2-antagonist, has shown potential in improving sleep quality in narcolepsy patients.

Purpose of the Study:

  • To evaluate the efficacy of ritanserin in improving daytime sleepiness, sleep quality, and other narcolepsy symptoms.
  • To assess ritanserin's effects on slow-wave sleep and NREM stage 1 sleep in narcolepsy patients.

Main Methods:

  • A double-blind, placebo-controlled, multi-center study involving 134 narcolepsy patients.
  • Patients received 5 mg or 10 mg ritanserin, or placebo, daily for 28 days, with stable concomitant medications allowed.
  • Efficacy was assessed using polysomnography, visual analogue scales, and patient/clinician-rated questionnaires.

Related Experiment Videos

Main Results:

  • Ritanserin significantly improved the feeling of being refreshed in the morning but did not improve other subjective narcolepsy symptoms.
  • Objective measures showed a significant increase in nocturnal slow-wave sleep and a reduction in NREM stage 1 sleep with ritanserin.
  • Subjective improvements in daytime sleepiness and sleep attacks were not observed, despite polysomnographic changes.

Conclusions:

  • Ritanserin may be beneficial as an add-on therapy for improving sleep quality in narcolepsy patients.
  • It does not appear to function as a stimulant or hypnotic medication for narcolepsy symptom management.